Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ultragenyx Pharma (RARE) Reports Q4 Loss of $0.37 on Revenues of $91.54M
February 11, 2021 4:45 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($0.37), versus ($1.62) reported last year. Revenue for the quarter came in at $91.54 million, versus $35.59 million reported last year.
Last year was a transformative year as we received two approvals, generated clinically meaningful data in our gene therapy and... More
